Latest From Aprea Therapeutics
Otsuka subsidiary Astex plans filing in MDS by year-end for first oral decitabine product on the back of positive Phase III comparative results.
Anthos premiers with $250m from Blackstone and cardiovascular disease assets and expertise from Novartis, while Maze brings in $191m for drugs that target gene modifiers. In public company financings, Sage raises $575m ahead of Zulresso approval decision.
2018 was a banner year for venture funding, and Relay's December Series C was only the third largest VC round of the year. Other year-end financings include Millendo, Erasca, Aristea and more...
Private Company Edition: Investments by CIRM, the GHIT fund and the European Investment Bank back early-stage science and treatments for neglected diseases. Also, Versant Ventures raises $700m in two funds. In VC deals, Akero raised $70m, Impel NeuroPharma brought in $67.5m.
- Therapeutic Areas
- Aprea AB
- Western Europe
- Parent & Subsidiaries
- Aprea Therapeutics
- Senior Management
Christian S Schade, Pres. & CEO
Lars Abrahmsen, PhD, SVP, CSO
Gregory A Korbel, PhD, VP, Bus. Dev.
Eyal C Attar , MD, SVP, CMO
- Contact Info
Phone: (46) 8 50884504
Karolinska Institute Science Park
Nobels väg 3
Solna, SE-171 65
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.